Literature DB >> 6124264

Labetalol in essential hypertension.

A Breckenridge, M Orme, M J Serlin, M Maciver.   

Abstract

1 Labetalol is an effective agent in essential hypertension as documented in open studies and controlled studies in which its efficacy has been compared with both placebo and a variety of other anti-hypertensive drugs. 2 Labetalol given by mouth lowers blood pressure rapidly. There is no evidence of tolerance to its anti-hypertensive action. 3 Adverse effects include excessive hypotension, but only when the drug is given in large doses. Epigastric discomfort and scalp tingling have been documented especially after intravenous administration. 4 From a pharmacokinetic and pharmacodynamic point of view, labetalol can be given once daily, but postural hypotension after large (greater than 1 g) single doses may limit the usefulness of once daily regimes. Twice daily administration appears an acceptable compromise.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6124264      PMCID: PMC1401833          DOI: 10.1111/j.1365-2125.1982.tb01887.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  14 in total

Review 1.  Labetalol: a review of its pharmacology and therapeutic use in hypertension.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1978-04       Impact factor: 9.546

2.  Double-blind trial of labetalol.

Authors:  J Kane; I Gregg; D A Richards
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

3.  Labetalol in long-term treatment of hypertension.

Authors:  B N Prichard; A J Boakes
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

4.  Combined alpha- and beta-adrenoceptor blockade with labetalol in hypertension.

Authors:  M H Frick; P Pörsti
Journal:  Br Med J       Date:  1976-05-01

5.  Antihypertensive effect of labetalol, a new alpha- and beta-adrenergic blocking agent.

Authors:  L Hansson; B Hänel
Journal:  Int J Clin Pharmacol Biopharm       Date:  1976-10

6.  Controlled comparison of labetalol and propranolol in the management of severe hypertension.

Authors:  D J Pugsley; B K Armstrong; M A Nassim; L J Beilin
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

7.  Experience with labetalol in hypertension.

Authors:  P Bolli; J Waal-Manning; A J Wood; F O Simpson
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

8.  Comparative anti-hypertensive effects of labetalol and the combination of oxprenolol and phentolamine.

Authors:  B F Johnson; J LaBrooy; A D Munro-Faure
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

9.  Labetalol compared with prindolol plus hydraliazine in the treatment of hypertension: a double-blind cross-over study.

Authors:  A J Barnett; S Kalowski; C Guest
Journal:  Med J Aust       Date:  1978-01-28       Impact factor: 7.738

10.  A study of labetalol in patients of European, West Indian and West African origin.

Authors:  K Jennings; V Parsons
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

View more
  1 in total

1.  Labetalol: the nineteen-eighties.

Authors:  J I Robertson
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.